Author + information
- Received October 8, 2019
- Revision received January 24, 2020
- Accepted February 3, 2020
- Published online April 27, 2020.
- Adam J. Nelson, BMedSc, MD, PhDa,
- Paolo Raggi, MDb,
- Myles Wolf, MD, MMScc,
- Alexander M. Gold, MDd,e,
- Glenn M. Chertow, MD, MPHe and
- Matthew T. Roe, MD, MHSa,∗ ()
- aDivision of Cardiology, Duke Clinical Research Institute, Durham, North Carolina
- bDivision of Cardiology, Department of Medicine, University of Alberta and Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada
- cDivision of Nephrology, Department of Medicine, and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- dResearch and Development, Sanifit Therapeutics, San Diego, California
- eDepartment of Medicine, Stanford University School of Medicine, Stanford, California
- ↵∗Address for correspondence:
Dr. Matthew T. Roe, Division of Cardiology, Duke Clinical Research Institute, 200 Morris Street, Durham, North Carolina 27701.
• Vascular calcification is a highly regulated, cell-mediated process that is strongly associated with CKD and confers increased risk for incident CV events.
• Multiple pathways link vascular calcification with CKD; however, they remain incompletely understood, and the development of targeted therapies has been underwhelming.
• Illumination of the causal steps and natural history that link vascular calcification to CV events will affirm its role as a CV risk factor and accelerate drug discovery and therapeutic translation.
Cardiovascular (CV) disease remains an important cause of morbidity and mortality for patients with chronic kidney disease (CKD). Although clustering of traditional risk factors with CKD is well recognized, kidney-specific mechanisms are believed to drive the disproportionate burden of CV disease. One perturbation that is frequently observed at high rates in patients with CKD is vascular calcification, which may be a central mediator for an array of CV sequelae. This review summarizes the pathophysiological bases of intimal and medial vascular calcification in CKD, current strategies for diagnosis and management, and posits vascular calcification as a risk marker and therapeutic target.
Dr. Raggi has been a member of the Advisory Board for Sanifit. Dr. Chertow has been an advisor for Sanifit. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received October 8, 2019.
- Revision received January 24, 2020.
- Accepted February 3, 2020.
- 2020 The Authors